{"filing":{"accession_number":"0001213900-26-070212","cik":"0001514183","ticker":"SILO","company_name":"Silo Pharma, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ea0295339-8k_silo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026070212/ea0295339-8k_silo.htm"},"events":[{"id":11988,"run_id":10549,"accession_number":"0001213900-26-070212","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that Silo Pharma has regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement after previously falling out of compliance in June 2025. While the current disclosure is positive (compliance restored), the underlying event—a delisting risk triggered by failure to maintain the $1.00 minimum bid price—is material to investors' assessment of the company's listing status and market viability. The company explicitly references the prior non-compliance letter and confirms that Nasdaq \"considers this matter closed,\" indicating resolution of a previously disclosed delisting threat.","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8717,"accession_number":"0001213900-26-070212","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Silo Pharma has regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement after previously falling out of compliance in June 2025. While the current disclosure is positive (compliance restored), the underlying event—a delisting risk triggered by failure to maintain the $1.00 minimum bid price—is material to investors' assessment of the company's listing status and market viability. The company explicitly references the prior non-compliance letter and confirms that Nasdaq \"considers this matter closed,\" indicating resolution of a previously disclosed delisting threat.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:16:09.918361+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8717,"accession_number":"0001213900-26-070212","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Silo Pharma has regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement after previously falling out of compliance in June 2025. While the current disclosure is positive (compliance restored), the underlying event—a delisting risk triggered by failure to maintain the $1.00 minimum bid price—is material to investors' assessment of the company's listing status and market viability. The company explicitly references the prior non-compliance letter and confirms that Nasdaq \"considers this matter closed,\" indicating resolution of a previously disclosed delisting threat.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:16:09.918361+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-18"}]}